socalTECH

AUGUST 20, 2013

Thousand Oaks-based Teledyne Technologies has acquired laboratory automation and instrument developer CETAC Technologies , the company annoucned this morning. Financial details of the buy were not announced. READ MORE>>. lifescience instrumentations automation laboratory acquisition merger cetac technologies teledyne'

Thousand Oaks 147

Thousand Oaks Technology Sample Acquisition 147

socalTECH

FEBRUARY 22, 2012

Thousand Oaks-based Ceres , the developer of specialized seeds for the biofuels market, has priced its IPO, saying that it will offer up 5,000,000 shares of its common stock at $13.00 The firm will start trading today on the NASDAQ Global Market as CERE. The IPO was underwritten by Goldman, Sachs & CO.,

Pricing 150

Pricing Thousand Oaks Startup Design 150

socalTECH

JANUARY 25, 2012

Thousand Oaks-based Ceres , the developer of seeds to supply the bioenergy and biofuels feedstock business, has set its initial pricing range for its IPO, according to a filing from the company this morning. Ceres has applied to list on the NASDAQ Global Market as CERE. and $23.00 READ MORE>>.

Pricing 145

Pricing Thousand Oaks Design Capital 145

socalTECH

JUNE 16, 2010

Thousand Oaks-bsaed Teledyne Technologies said late Tuesady evening that it is acquiring Swindon, United Kingdom-based INtelek plc , a firm which designs and manufactures electronics systems for satellite and microwave communications. The deal is worth approximately $52.0M.

Thousand Oaks 159

Thousand Oaks Technology Acquisition Design 159

socalTECH

MAY 18, 2009

Thousand Oaks-based Xirrus , a developer of Wi-Fi networking equipment, announced Monday that it has put together a portable, pre-packaged kit which is designed for deploying Wi-Fi into disaster response and temporary events. The firm said it would offer the new product online, priced starting at $3,999.

Organization 100

Organization Thousand Oaks Conference Networking 100

Xconomy

SEPTEMBER 30, 2016

Who will be first to market with a new type of cancer treatment known as CAR-T? Who will break free of the pack of companies developing drugs meant to prevent migraines? —Sarepta inked a research pact with Catabasis Pharmaceuticals (NASDAQ: CATB ) to develop a combination therapy for Duchenne. TheStreet.com has more here.

Avalon 40

Avalon Thousand Oaks Study Startup 40